Biolase gets US nod for eye laser:
This article was originally published in Clinica
Executive Summary
Marking an "important milestone in its ophthalmic pursuits", Biolase Technology, a company that makes laser systems for use primarily in dentistry, has gained US clearance to sell its Oculase MD laser system for general ophthalmic soft tissue surgical indications. The approval represents an "early achievement along the path to developing a treatment for presbyopia", said the Irvine, California firm. It also enables Biolase to pursue other applications using its core technology in ophthalmology, and will improve its ability to move forward with its clinical research and sales and marketing initiatives for Oculase MD, both domestically and internationally, said the company. Oculase MD is the first Er,Cr:YSGG laser system cleared for ophthalmic applications, Biolase added.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.